After working with Lilly, the local drug company is 'married' to Roche

on June 9, Cinda Bio announced that InnoventBiologics (HK) Limited, a wholly owned subsidiary of the company, has reached a strategic cooperation agreement with Roche Group focusing on research, clinical development and commercialization of multiple bispecific antibody and cell therapy products that will be used directly in blood and solid tumor therapyit is understood that the partnership will use Roche's "2-1" dual-specific antibody platform, combined with the high-quality new targets developed by Cinda Bio, to create a dual-anti-field T cell interface antibody (T cell engager), covering 2 productsIn fact, Cinda has been in the field of bi-anti-resistance, and there are already six bispecific antibody drugs in developmentThis collaboration with Roche Pharmaceuticals is an internationally competitive, different from traditional dual-resistance technology that promises to address clinically unmet tumor typesCinda Bio said that through this strategic partnership, the group will further enhance its cell therapy discovery platform and enrich its select ediphon of unique dual-specific molecular products, promising to benefit more patients worldwideUnder the terms of the agreement, Innovent HK will pay down payment, development and commercialization milestone payments, and product sales commissions for its non-sole use of roche technologies to discover and develop 2:1 bispecific TCELL Antibodies (TCB) and universal CAR-T platformsInnovent HK will develop, produce and commercialize these productsRoche reserves the option to repurchase each product's development and commercialization interests outside ChinaIf Roche exercises all its options, it will pay a total of $140 million to Innovent HKAnd, if all products are successfully developed and commercialized, a total of approximately $1.96 billion in product development, approval and sales will be paid, in addition to a double-digit sales increase for each productit is worth mentioning that this is also a large-scale foreign cooperation program for Cinda Bio and Lilly after three comprehensive cooperationMarch 2015, Lilly Pharmaceuticals and Cinda Bio reached a partnership for biotechnology drug development in which Lilly Pharmaceuticals and Cinda Bio will jointly develop and commercialize oncology drugs in China, including Daberschu (Cindilly SYNDOe)In October 2015, the two sides announced the expansion of established drug development cooperation to add three new tumor treatment antibodiesIn August 2019, the partnership expanded into the field of diabetes, and Cinda Bio was authorized to develop and commercialize a potential new global clinical stage diabetes drug in Chinaindustry said the three collaborations with Lilly Pharmaceuticals marked the establishment of a comprehensive strategic partnership between China's innovative pharmaceutical companies and the global pharmaceutical giants, covering new drug development, clinical research, production quality and marketingwith Cinda Bio and Roche "marriage", meaning that Cinda Bio's external cooperation a step further, Cinda Bio has thus become one of the few domestic and the two world pharmaceutical giants to reach strategic cooperation with the pharmaceutical companies This collaboration means that Cinda Bio will take an important step forward in the construction of a cell therapy discovery platform and an innovative dual-specific antibody product chain information shows that Cinda Bio was founded in 2011 to develop, produce and sell innovative drugs for the treatment of major diseases such as cancer, autoimmune and metabolic diseases On October 31, 2018, Cinda Biopharmaceuticals was listed on the Main Board of the Stock Exchange of Hong Kong Limited.